There is no more stable growing sector of in vitro diagnostics than infectious disease testing.
That’s because new threats, improved devices, and the increased global funding of new testing all point towards a reliable increase in revenues for infectious disease IVD companies. It’s also a market that has shown it can support a large base of companies, including new entrants.
To guide you though this market opportunity, trust the brand that provides the news coverage that you trust. EYE ON IVD’S INFECTIOUS DISEASE IVD MARKET REVIEW REPORT, developed by analysts with two decades of experience in the market, provides a superior quality reference tool for business planning and forecasting, market assessment and product management.
Those who follow EYE ON IVD newsletter’s cutting analysis will know this is resource as a thorough market review designed by IVD industry experts, not a report by a market research compiler that produces thousands of reports. The report reveals over a dozen infectious disease areas that beat growth in the IVD market, including some testing areas that are doubling or tripling the revenue growth of the market.
Disease Markets Estimated and Forecasted in this comprehensive report include:
HIV (Molecular and Immunoassay), 2019 to 2035
Hepatitis (By Type), 2019 to 2035
STIs (Chlamydia, HPV, Gonorrhea, Trichomoniasis, HSV, Syphilis), 2019 to 2035
HAIs (C. diff., Sepsis, MRSA, VRE, Other), 2019 to 2035
Respiratory (RSV, Influenza, COVID, Others), 2019 to 2035
TORCH Testing (POC and Lab-based), 2019 to 2035
ID/AST Testing (Automated/Manual), 2019 to 2035
Non-Lyme Parasitic Infections, 2019 to 2035
- Gastrointestinal Infections, 2019 to 2035
Fungal Infections, 2019 to 2035
Tuberculosis, 2019 to 2035
Malaria, 2019 to 2035
Other Infectious Diseases (West Nile, Chagas, Dengue, Zika, Marburg, Ebola, Other Emerging), 2019 to 2035
The report analyzes trends, such as the drop in COVID revenues, and how IVDs are doing replacing that revenue. It looks at the current state of the China IVD market, and how infectious disease scares are creating opportunity for large concerns. The report also profiles top companies in the market, and looks at with 20 disease areas and 21 country and regions market, the report offers exceptional coverage.
IVD is a global market, and this superior report reflects that the international market may offer different opportunities than the United States or European markets. Country market are estimated from 2018 to 2031. (reflecting greater possibility of forecast change and country developments).
Country and Region Markets Include:
United States
Canada
Mexico
UK
Germany
France
Spain
Italy
Eastern Europe
Latin America
Middle East and Africa
China
Japan
South Korea
Saudi Arabia
(For each country/region – the report breaks out: Respiratory, STIs, HAIs, ID/AST, Hepatitis, AIDS/HIV, Influenza, Tuberculosis, TORCH, Other)
There are many approaches to testing for infectious disease, each with its own markets and sub markets. This report breaks out markets by type of product to accomodate this level of business planning, including Panel vs. non-Panel, molecular and immunoassay, POC/Lab. Also included in the report is a breakout of competition.
Companies in the Market w/ Recent Developments and 2023 Revenues
Companies to Watch, w/ important innovations and milestones.
EXECUTIVE SUMMARY
Key Points
Infectious IVD Market, 2019-2035
Infectious IVD Market Growth Rate
Infectious IVD Market Compared to IVD Market
Growth Rates by Type (Respiratory Tests, Sexually Transmitted Infections, Hospital Acquired Infection, ID/AST, Hepatitis, AIDS/HIV, Lyme, TORCH, Malaria, Others, Total (w/COVID and without)
- Growth Trends by Geography
- Near Term Growth Trend by Test Type (TB, Influenza, HAIs, STIs, AIDS, TORCH, Other)
- Developing vs. Non-Developing World Infectious Disease IVD Market, Trend
- Developing vs. Non-Developing World Infectious Disease IVD Market, %
- Molecular Trend (Respiratory, STI, HAI, Hepatitis, AIDS/HIV, Lyme, TORCH, Malaria, Other)
- 20+ High-Growth Infectious Disease IVD Test Categories
- Top Companies in the Market
- Top Companies Share of Overall IVD Market
- Table – Market for Infectious Disease IVD by Type, 2019-2035
TOP TRENDS
Summary of Top Trends
Drop in COVID-19 Revenues
Recent Infectious Disease Scares
New STD Recommendations
New Hepatitis Recommendations
New TB Recommendations
WHO HAI Recommendation
Consolidations of Laboratories and IVD
PAMA, LDTS and IVDR
IVDR Delay
Changeover to Medicare Advantage
Changeover to Medicare Advantage, Impact to Labs
China More Challenging Market
China Mixed Company Results
AI Developments
WHO AI Standards
Developments in ID-IVD Testing
INDICATORS DATA
Indicators: Population (North America, United States, Canada, Mexico, Western Europe, Germany, France, United Kingdom, Italy, Spain, Other Western Europe, Asia/Pacific, China, India, Japan, South Korea, Other Asia/Pacific, Other Regions, Central & South America, Eastern Europe, Africa/Middle East)
Indicators: US Population (North America, United States, Canada, Mexico, Western Europe, Germany, France, United Kingdom, Italy, Spain, Other Western Europe, Asia/Pacific, China, India, Japan, South Korea, Other Asia/Pacific, Other Regions, Central & South America, Eastern Europe, Africa/Middle East)
Indicators: World Population (North America, United States, Canada, Mexico, Western Europe, Germany, France, United Kingdom, Italy, Spain, Other Western Europe, Asia/Pacific, China, India, Japan, South Korea, Other Asia/Pacific, Other Regions, Central & South America, Eastern Europe, Africa/Middle East)
Indicators GDP (North America, United States, Canada, Mexico, Western Europe, Germany, France, United Kingdom, Italy, Spain, Other Western Europe, Asia/Pacific, China, India, Japan, South Korea, Other Asia/Pacific, Other Regions, Central & South America, Eastern Europe, Africa/Middle East)
Indicators: Per Capita GDP (North America, United States, Canada, Mexico, Western Europe, Germany, France, United Kingdom, Italy, Spain, Other Western Europe, Asia/Pacific, China, India, Japan, South Korea, Other Asia/Pacific, Other Regions, Central & South America, Eastern Europe, Africa/Middle East)
Trend in Per Capita GDP
Indicators: Healthcare Expenditure (North America, United States, Canada, Mexico, Western Europe, Germany, France, United Kingdom, Italy, Spain, Other Western Europe, Asia/Pacific, China, India, Japan, South Korea, Other Asia/Pacific, Other Regions, Central & South America, Eastern Europe, Africa/Middle East)
Indicators: Infectious Disease Cases (North America, United States, Canada, Mexico, Western Europe, Germany, France, United Kingdom, Italy, Spain, Other Western Europe, Asia/Pacific, China, India, Japan, South Korea, Other Asia/Pacific, Other Regions, Central & South America, Eastern Europe, Africa/Middle East)
Infectious Disease Cases by Region (North America, United States, Canada, Mexico, Western Europe, Germany, France, United Kingdom, Italy, Spain, Other Western Europe, Asia/Pacific, China, India, Japan, South Korea, Other Asia/Pacific, Other Regions, Central & South America, Eastern Europe, Africa/Middle East)
Indicators: Hospitals (North America, United States, Canada, Mexico, Western Europe, Germany, France, United Kingdom, Italy, Spain, Other Western Europe, Asia/Pacific, China, India, Japan, South Korea, Other Asia/Pacific, Other Regions, Central & South America, Eastern Europe, Africa/Middle East)
Indicators: Outpatient Consultations (North America, United States, Canada, Mexico, Western Europe, Germany, France, United Kingdom, Italy, Spain, Other Western Europe, Asia/Pacific, China, India, Japan, South Korea, Other Asia/Pacific, Other Regions, Central & South America, Eastern Europe, Africa/Middle East)
IVD MARKETS BY DISEASE
Key Points: IVD Markets by Disease
Respiratory IVD Market, 2019-2035
By Technology: Immunoassay, Molecular, Microbiology
By Condition: COVID-19, Influenza, Tuberculosis, RSV, Pneumonia, All Other
By Site: Laboratory, Point of Care
By Type: Single Reagent, Reagent Panels
Sexually Transmitted Infections Market IVD Market, 2019-2035
By Technology: Immunoassay, Molecular, Microbiology
By Site: Laboratory, Point of Care
By Condition: Chlamydia, HPV, Gonorrhea, Trichomoniasis, HSV, Syphilis, Other
By Type: Single Reagent, Reagent Panels
Total
Healthcare Acquired Infections IVD Market, 2019-2035
By Technology: Molecular, Microbiology, Immunoassay
By Site: Laboratory, Point of Care
By Condition: C. diff, Sepsis, MRSA, VRE, Other
By Type: Single Reagent, Reagent Panels
Total
ID/Antibiotic Susceptibility Testing Market, 2019-2035
By Product:
Automated Tests
Manual Tests
Hepatitis IVD Testing Market, 2019-2035
By Technology:
Molecular
Immunoassay
By Site:
Laboratory
Blood Screening Sites
Point of Care
By Pathogen:
Hepatitis B
Hepatitis C
Other
By Type:
Single Reagent
Reagent Panels
HIV/AIDS IVD Testing Market, 2019-2035
By Technology:
Immunoassay
Molecular
By Site:
Laboratory
Blood Screening Sites
Point of Care
Lyme Disease Testing:
By Technology:
Immunoassay
Molecular
Microbiology
By Site:
Laboratory
Point of Care
TORCH Screening:
By Technology:
Immunoassay
Molecular
By Site:
Laboratory
Point of Care
Malaria Testing:
By Technology:
Microbiology
Molecular
Immunoassay
By Site:
Laboratory
Point of Care
Other Infectious Disease Testing:
By Technology:
Immunoassay
Molecular
Microbiology
By Condition:
Non-Lyme Parasitic Infections
Dengue
Gastrointestinal Infections
Fungal Infections
Zika Virus
Marburg Viral Infections
West Nile Virus
Ebola
Chagas Infections
All Other Infections
By Site:
Laboratory
Point of Care
Total
Item/Year
Molecular IVD Product Demand
Respiratory Infections
Sexually Transmitted Infections
Healthcare-Acquired Infections
Hepatitis
AIDS/HIV
Lyme Disease
TORCH
Malaria
Other
Total
Item/Year
Microbiology IVD Product Demand
Respiratory Infections
Sexually Transmitted Infections
Healthcare-Acquired Infections
ID/Antibiotic Susceptibility Testing
Lyme Disease
Malaria
Other
Total
Item/Year
Laboratory IVD Product Demand:
Respiratory Infections
Sexually Transmitted Infections
Healthcare-Acquired Infections
ID/Antibiotic Susceptibility Testing
Hepatitis
AIDS/HIV
Lyme Disease
TORCH
Malaria
Other
Total
Item/Year
Point of Care IVD Product Demand*
Respiratory Infections
Sexually Transmitted Infections
Healthcare-Acquired Infections
Hepatitis
AIDS/HIV
Lyme Disease
TORCH
Malaria
Other
Total
COUNTRY MARKETS
World Infectious Disease Testing IVD Products Demand (million dollars)
Item/Year
STIs
HAIs
ID/AST
Hepatitis
AIDS/HIV
Influenza
Tuberculosis
TORCH
Other
Total w/o COVID-19
COVID-19
Total w/COVID-19
North America Infectious Disease Testing IVD Products Demand (million dollars)
Item/Year
STIs
HAIs
ID/AST
Hepatitis
AIDS/HIV
Influenza
Tuberculosis
TORCH
Other
Total w/o COVID-19
COVID-19
Total w/COVID-19
United States: Infectious Disease Testing IVD Products Demand (million dollars)
Item/Year
STIs
HAIs
ID/AST
Hepatitis
AIDS/HIV
Influenza
Tuberculosis
TORCH
Other
Total w/o COVID-19
COVID-19
Total w/COVID-19
Canada: Infectious Disease Testing IVD Products Demand (million dollars)
Item/Year
STIs
HAIs
ID/AST
Hepatitis
AIDS/HIV
Influenza
Tuberculosis
TORCH
Other
Total w/o COVID-19
COVID-19
Total w/COVID-19
Mexico: Infectious Disease Testing IVD Products Demand (million dollars)
Item/Year
STIs
HAIs
ID/AST
Hepatitis
AIDS/HIV
Influenza
Tuberculosis
TORCH
Other
Total w/o COVID-19
COVID-19
Total w/COVID-19
Western Europe: Infectious Disease Testing IVD Products Demand (million dollars)
Item/Year
STIs
HAIs
ID/AST
Hepatitis
AIDS/HIV
Influenza
Tuberculosis
TORCH
Other
Total w/o COVID-19
COVID-19
Total w/COVID-19
Germany: Infectious Disease Testing IVD Products Demand (million dollars)
Item/Year
STIs
HAIs
ID/AST
Hepatitis
AIDS/HIV
Influenza
Tuberculosis
TORCH
Other
Total w/o COVID-19
COVID-19
Total w/COVID-19
France: Infectious Disease Testing IVD Products Demand (million dollars)
Item/Year
STIs
HAIs
ID/AST
Hepatitis
AIDS/HIV
Influenza
Tuberculosis
TORCH
Other
Total w/o COVID-19
COVID-19
Total w/COVID-19
United Kingdom: Infectious Disease Testing IVD Products Demand (million dollars)
Item/Year
STIs
HAIs
ID/AST
Hepatitis
AIDS/HIV
Influenza
Tuberculosis
TORCH
Other
Total w/o COVID-19
COVID-19
Total w/COVID-19
Italy: Infectious Disease Testing IVD Products Demand (million dollars)
Item/Year
STIs
HAIs
ID/AST
Hepatitis
AIDS/HIV
Influenza
Tuberculosis
TORCH
Other
Total w/o COVID-19
COVID-19
Total w/COVID-19
Spain: Infectious Disease Testing IVD Products Demand (million dollars)
Item/Year
STIs
HAIs
ID/AST
Hepatitis
AIDS/HIV
Influenza
Tuberculosis
TORCH
Other
Total w/o COVID-19
COVID-19
Total w/COVID-19
Other Western Europe: Infectious Disease Testing IVD Products Demand (million dollars)
Item/Year
STIs
HAIs
ID/AST
Hepatitis
AIDS/HIV
Influenza
Tuberculosis
TORCH
Other
Total w/o COVID-19
COVID-19
Total w/COVID-19
Asia/Pacific: Infectious Disease Testing IVD Products Demand (million dollars)
Item/Year
STIs
HAIs
ID/AST
Hepatitis
AIDS/HIV
Influenza
Tuberculosis
TORCH
Other
Total w/o COVID-19
COVID-19
Total w/COVID-19
China: Infectious Disease Testing IVD Products Demand (million dollars)
Item/Year
STIs
HAIs
ID/AST
Hepatitis
AIDS/HIV
Influenza
Tuberculosis
TORCH
Other
Total w/o COVID-19
COVID-19
Total w/COVID-19
India: Infectious Disease Testing IVD Products Demand (million dollars)
Item/Year
STIs
HAIs
ID/AST
Hepatitis
AIDS/HIV
Influenza
Tuberculosis
TORCH
Other
Total w/o COVID-19
COVID-19
Total w/COVID-19
Japan: Infectious Disease Testing IVD Products Demand (million dollars)
Item/Year
STIs
HAIs
ID/AST
Hepatitis
AIDS/HIV
Influenza
Tuberculosis
TORCH
Other
Total w/o COVID-19
COVID-19
Total w/COVID-19
South Korea: Infectious Disease Testing IVD Products Demand (million dollars)
Item/Year
STIs
HAIs
ID/AST
Hepatitis
AIDS/HIV
Influenza
Tuberculosis
TORCH
Other
Total w/o COVID-19
COVID-19
Total w/COVID-19
Other Asia/Pacific: Infectious Disease Testing IVD Products Demand (million dollars)
Item/Year
STIs
HAIs
ID/AST
Hepatitis
AIDS/HIV
Influenza
Tuberculosis
TORCH
Other
Total w/o COVID-19
COVID-19
Total w/COVID-19
Other Regions: Infectious Disease Testing IVD Products Demand (million dollars)
Item/Year
STIs
HAIs
ID/AST
Hepatitis
AIDS/HIV
Influenza
Tuberculosis
TORCH
Other
Total w/o COVID-19
COVID-19
Total w/COVID-19
Central & South America: Infectious Disease Testing IVD Products Demand (million dollars)
Item/Year
STIs
HAIs
ID/AST
Hepatitis
AIDS/HIV
Influenza
Tuberculosis
TORCH
Other
Total w/o COVID-19
COVID-19
Total w/COVID-19
Eastern Europe: Infectious Disease Testing IVD Products Demand (million dollars)
Item/Year
STIs
HAIs
ID/AST
Hepatitis
AIDS/HIV
Influenza
Tuberculosis
TORCH
Other
Total w/o COVID-19
COVID-19
Total w/COVID-19
Africa/Mideast: Infectious Disease Testing IVD Products Demand (million dollars)
Item/Year
STIs
HAIs
ID/AST
Hepatitis
AIDS/HIV
Influenza
Tuberculosis
TORCH
Other
Total w/o COVID-19
COVID-19
Total w/COVID-19
Infectious Disease IVD Product Demand by Country Region (million dollars)
Country/Year
North America:
United States
Canada
Mexico
Western Europe:
Germany
France
United Kingdom
Italy
Spain
Other Western Europe
Asia/Pacific:
China
India
Japan
South Korea
Other Asia/Pacific
Other Regions:
Cent & South America
Eastern Europe
Africa/Middle East
Total World
Bruce Carlson, project lead of Infectious Disease Diagnostics Market Review, has 18+ years experience in developing market research for in vitro diagnostic clients. He heads up Eye On IVD, LLC. Previously, Carlson worked at Kalorama Information as publisher and Senior Vice President for SMG. He has been employed at WebMD, Scientific American and Market Research.com.
Carlson works with expert analysts to craft industry-relatable numbers that can be useful for business planning activities. Carlson has developed a wide variety of in vitro diagnostic and healthcare reports, including reports on: contract manufacturing in IVD, IVD and urgent cares, point-of-care testing, overall IVD markets and veterinary IVD testing.
Carlson has appeared in Genetic Engineering News, Wired Magazine, Becker’s Hospital Weekly, Pharma Times, Pharma News and other media outlets. He routinely conducts webinars related to IVD. His newsletter, IVD has hundreds of readers. Carlson covers the ADLM meeting each year as authorized press representative.
